Bracco sells Esaote subsidiary to investment group
Esaote, known worldwide for its MR and ultrasound equipment, has split from its Italian parent, the Bracco Group. The company was sold Jan. 20 for an undisclosed amount to a group of investors led by Esaote chairman and CEO Carlo Castellano.
Esaote, known worldwide for its MR and ultrasound equipment, has split from its Italian parent, the Bracco Group. The company was sold Jan. 20 for an undisclosed amount to a group of investors led by Esaote chairman and CEO Carlo Castellano.
Eighty shareholders in the newly independent Esaote are company staff, described by Castellano as "white collars, managers, and top executives." Castellano gives the company high marks in teamwork and commitment to innovation.
"The key success factors of the Esaote group are the quality of the medical equipment and the know-how in the software applied to diagnostics," he said.
Esaote provides specialty MR scanners dedicated to extremity imaging, as well as diagnostic ultrasound equipment and electrocardiography systems.
The divestment of Esaote reflects efforts by Bracco to focus on core capabilities and selected emerging technologies. The company is concentrating particularly on devices oriented toward the administration of diagnostic contrast agents and high-tech adjuncts to therapy.
Editor's note: DI SCAN will profile Esaote, strategic developments at Bracco, and the deal that split these two companies apart in its next issue, Feb. 6.
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.
